Short Interest in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Rises By 77.9%

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the recipient of a large increase in short interest in March. As of March 15th, there was short interest totalling 112,600 shares, an increase of 77.9% from the February 29th total of 63,300 shares. Based on an average trading volume of 114,500 shares, the short-interest ratio is currently 1.0 days. Approximately 0.9% of the shares of the company are short sold.

Cyclo Therapeutics Stock Down 0.7 %

Cyclo Therapeutics stock traded down $0.01 during trading hours on Thursday, hitting $1.39. The stock had a trading volume of 30,476 shares, compared to its average volume of 101,754. The company has a 50-day moving average of $1.67 and a two-hundred day moving average of $1.48. The company has a market cap of $39.92 million, a PE ratio of -1.07 and a beta of -0.14. Cyclo Therapeutics has a fifty-two week low of $0.67 and a fifty-two week high of $2.57.

Hedge Funds Weigh In On Cyclo Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its holdings in Cyclo Therapeutics by 14.3% in the 1st quarter. Renaissance Technologies LLC now owns 75,787 shares of the company’s stock valued at $240,000 after acquiring an additional 9,487 shares in the last quarter. Northern Trust Corp acquired a new position in shares of Cyclo Therapeutics in the 2nd quarter worth approximately $26,000. Vanguard Group Inc. raised its holdings in shares of Cyclo Therapeutics by 8.3% in the 3rd quarter. Vanguard Group Inc. now owns 282,027 shares of the company’s stock worth $400,000 after buying an additional 21,650 shares in the last quarter. Citadel Advisors LLC raised its holdings in shares of Cyclo Therapeutics by 282.1% in the 4th quarter. Citadel Advisors LLC now owns 54,018 shares of the company’s stock worth $86,000 after buying an additional 39,881 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Cyclo Therapeutics by 92.1% in the 2nd quarter. Geode Capital Management LLC now owns 100,388 shares of the company’s stock worth $160,000 after buying an additional 48,135 shares in the last quarter. Institutional investors and hedge funds own 68.55% of the company’s stock.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.